東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Economics of breast cancer preventiv...

Borker, Rohit D.

FindBook

Google Book

Amazon

博客來

Economics of breast cancer preventive strategies in a Medicaid program.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Economics of breast cancer preventive strategies in a Medicaid program./
作者:	Borker, Rohit D.
面頁冊數:	168 p.
附註:	Source: Dissertation Abstracts International, Volume: 65-01, Section: B, page: 0178.
Contained By:	Dissertation Abstracts International65-01B.
標題:	Health Sciences, Pharmacy. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3118655
ISBN:	0496660780

Economics of breast cancer preventive strategies in a Medicaid program.
Borker, Rohit D.

Economics of breast cancer preventive strategies in a Medicaid program. - 168 p.

Source: Dissertation Abstracts International, Volume: 65-01, Section: B, page: 0178.

Thesis (Ph.D.)--West Virginia University, 2003.

The primary objective of the study was to estimate the long-term benefits and costs of chemopreventive tamoxifen and mammography screening in women who are otherwise healthy but at high risk of developing breast cancer. Three hypothetical cohorts of high-risk women were initiated at age forty. The first cohort consumed chemopreventive tamoxifen and underwent routine mammography screening. The second cohort also consumed chemopreventive tamoxifen but underwent mammography screening at real-world rates. The third cohort (control cohort) did not consume chemopreventive tamoxifen and underwent mammography screening at real-world rates. The study also assessed the proportion of women in the West Virginia Medicaid Program (WVMP) who were healthy but at a high risk of developing breast cancer. Secondary objectives of the study involved determining breast cancer knowledge, utilization of breast cancer preventive strategies, and willingness to consume chemopreventive tamoxifen. Chemopreventive tamoxifen coupled with routine mammography screening resulted in an incremental life expectancy gain of 0.122 years at an incremental cost of

ISBN: 0496660780Subjects--Topical Terms:

1017737
Health Sciences, Pharmacy.

Economics of breast cancer preventive strategies in a Medicaid program.
LDR:03376nmm 2200289 4500 001 1842907
005 20050928072451.5
008 130614s2003 eng d
020 $a 0496660780
035 $a (UnM)AAI3118655
035 $a AAI3118655
040 $a UnM $c UnM
100 1 $a Borker, Rohit D. $3 1931151
245 1 0 $a Economics of breast cancer preventive strategies in a Medicaid program.
300 $a 168 p.
500 $a Source: Dissertation Abstracts International, Volume: 65-01, Section: B, page: 0178.
500 $a Chair: Suresh Madhavan.
502 $a Thesis (Ph.D.)--West Virginia University, 2003.
520 $a The primary objective of the study was to estimate the long-term benefits and costs of chemopreventive tamoxifen and mammography screening in women who are otherwise healthy but at high risk of developing breast cancer. Three hypothetical cohorts of high-risk women were initiated at age forty. The first cohort consumed chemopreventive tamoxifen and underwent routine mammography screening. The second cohort also consumed chemopreventive tamoxifen but underwent mammography screening at real-world rates. The third cohort (control cohort) did not consume chemopreventive tamoxifen and underwent mammography screening at real-world rates. The study also assessed the proportion of women in the West Virginia Medicaid Program (WVMP) who were healthy but at a high risk of developing breast cancer. Secondary objectives of the study involved determining breast cancer knowledge, utilization of breast cancer preventive strategies, and willingness to consume chemopreventive tamoxifen. Chemopreventive tamoxifen coupled with routine mammography screening resulted in an incremental life expectancy gain of 0.122 years at an incremental cost of $5 ,969.70 resulting in an incremental cost effectiveness ratio (ICER) of $4 8,931.80 per life year gained (3% discount rate) as compared to control cohort. Chemopreventive tamoxifen coupled with mammography screening at real-world rates resulted in an incremental life expectancy gain of 0.076 years at an incremental cost of $4 ,916.84 resulting in an incremental cost effectiveness ratio (ICER) of $6 4,695.20 per life year gained (3% discount rate) as compared to control cohort. Sensitivity analysis indicated robustness of results over a wide rage of assumptions. About half of the surveyed population was at a high risk of developing breast cancer and thus eligible to receive chemopreventive tamoxifen. However, only about 17% respondents indicated their inclination towards consuming chemopreventive tamoxifen. A low but significant correlation was observed between the respondent's perceived risk and real risk indicating the need for increasing breast cancer awareness. Respondent's actual risk of developing breast cancer did not appear to have any relationship with willingness to consume chemopreventive tamoxifen. In summary, chemopreventive tamoxifen plus mammography screening in high-risk women is a cost-effective strategy. However, at present, very few of these high-risk women may actually utilize chemoprevention.
590 $a School code: 0256.
650 4 $a Health Sciences, Pharmacy. $3 1017737
650 4 $a Health Sciences, Health Care Management. $3 1017922
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0572
690 $a 0769
690 $a 0992
710 2 0 $a West Virginia University. $3 1017532
773 0 $t Dissertation Abstracts International $g 65-01B.
790 1 0 $a Madhavan, Suresh, $e advisor
790 $a 0256
791 $a Ph.D.
792 $a 2003
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3118655